The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
ERS clinical practice guidelines on treatment of sarcoidosis
Open accessAbstract
Background: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations. Methods: A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations. Results: The Task Force committee delivered 12 recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac and neurologic disease as well as fatigue. One PICO question regarding small-fibre neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation. Conclusions: There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citation(1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.ats4-99 · Cited by 1,902
Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis
BAUGHMAN, R. P., TEIRSTEIN, A. S., JUDSON, M. A., ROSSMAN, M. D., YEAGER, H., BRESNITZ, E. A., DePALO, L., HUNNINGHAKE, G., IANNUZZI, M. C., JOHNS, C. J., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.10.2104046 · Cited by 1,808
Self-citation
Research works printed but not linked: 60
- 10.1183/16000617.0145-2019 · doi:10.1183/16000617.0145-2019
- 10.1183/23120541.00141-2018 · doi:10.1183/23120541.00141-2018
- 10.1378/chest.128.2.1062 · DOI · Paper page
- 10.1093/qjmed/hcl038 · doi:10.1093/qjmed/hcl038
- 10.1212/WNL.0000000000004644 · doi:10.1212/wnl.0000000000004644
- 10.1378/chest.125.3.990 · doi:10.1378/chest.125.3.990
- Baughman, 2020, Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a 6 year period, Sarcoidosis Vasc Diffuse Lung Dis, 37, e2020001
- Drent, 2014, Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 31, 91
- Lower, 2020, Use of third-line therapies in advanced sarcoidosis, Clin Exp Rheumatol, 38, 834
- Baughman, 2004, Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 21, 43
- Muers, 1997, A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society study of long-term corticosteroid treatment, Sarcoidosis Vasc Diffuse Lung Dis, 14, 46
- 10.2165/00128071-200809030-00003 · doi:10.2165/00128071-200809030-00003
- 10.1183/13993003.00897-2019 · doi:10.1183/13993003.00897-2019
- 10.1016/S0140-6736(67)90493-X · doi:10.1016/s0140-6736(67)90493-x
- 10.1378/chest.116.2.424 · doi:10.1378/chest.116.2.424
- Zaki, 1987, Corticosteroid therapy in sarcoidosis: a 5 year controlled follow-up, NY State J Med, 87, 496
- 10.7326/0003-4819-73-2-207 · doi:10.7326/0003-4819-73-2-207
- 10.1111/j.1365-2796.1994.tb00798.x · doi:10.1111/j.1365-2796.1994.tb00798.x
- Baughman, 2002, Use of fluticasone in acute symptomatic pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 19, 198
- Baughman, 2014, Features of sarcoidosis associated with chronic disease, Sarcoidosis Vasc Diffuse Lung Dis, 31, 275
- 10.1136/pgmj.46.538.537 · doi:10.1136/pgmj.46.538.537
- Selroos, 1979, Corticosteroid therapy of pulmonary sarcoidosis, Scand J Respir Dis, 60, 215
- 10.1016/0002-9343(66)90216-6 · doi:10.1016/0002-9343(66)90216-6
- Rossman, 2006, A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 23, 201
- 10.1001/archinte.1995.00430080088011 · doi:10.1001/archinte.1995.00430080088011
- Fang, 2019, Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study, Sarcoidosis Vasc Diffuse Lung Dis, 36, 217
- Siltzbach, 1964, Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis, Acta Med Scand, 425, 302S, 10.1111/j.0954-6820.1964.tb05780.x · doi:10.1111/j.0954-6820.1964.tb05780.x
- Minnis, 2016, Adalimumab for refractory pulmonary sarcoidosis, Ir J Med Sci, 185, 969, 10.1007/s11845-015-1363-9 · doi:10.1007/s11845-015-1363-9
- 10.1183/09031936.00224513 · doi:10.1183/09031936.00224513
- Drake, 2013, Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 30, 201
- Drake, 2021, Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis, Chest, 159, 1902, 10.1016/j.chest.2020.12.027 · doi:10.1016/j.chest.2020.12.027
- Irwin, 2018, Higher priced older pharmaceuticals: how should we respond?, Chest, 153, 23, 10.1016/j.chest.2017.09.042 · doi:10.1016/j.chest.2017.09.042
- 10.1016/j.ccm.2015.08.010 · doi:10.1016/j.ccm.2015.08.010
- 10.1001/archdermatol.2011.2085 · doi:10.1001/archdermatol.2011.2085
- Chang, 2012, Cutaneous sarcoidosis: a case series from a regional hospital in Hong Kong, Hong Kong J Dermatol Venereol, 20, 153
- Tong, 2014, Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis, Int J Clin Exp Pathol, 7, 372
- Collin, 2010, A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department, Clin Exp Dermatol, 35, 131, 10.1111/j.1365-2230.2009.03400.x · doi:10.1111/j.1365-2230.2009.03400.x
- Volden, 1992, Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing, Acta Derm Venereol, 72, 69, 10.2340/00015555726971 · doi:10.2340/00015555726971
- 10.1001/archderm.131.5.617 · doi:10.1001/archderm.131.5.617
- 10.1016/j.jaad.2006.06.019 · doi:10.1016/j.jaad.2006.06.019
- Noe, 2017, High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 34, 136
- Droitcourt, 2014, A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis, Chest, 146, 1046, 10.1378/chest.14-0015 · doi:10.1378/chest.14-0015
- 10.1016/S0041-3879(67)80033-3 · doi:10.1016/s0041-3879(67)80033-3
- Jones, 1990, Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas, J Am Acad Dermatol, 23, 487, 10.1016/0190-9622(90)70246-E · doi:10.1016/0190-9622(90)70246-e
- 10.1016/0190-9622(91)70071-9 · doi:10.1016/0190-9622(91)70071-9
- 10.1016/S0022-3476(97)70306-8 · doi:10.1016/s0022-3476(97)70306-8
- Rajendran, 1994, Methotrexate in the treatment of cutaneous sarcoidosis, Sarcoidosis, 11, S335
- 10.1016/j.jcmg.2017.04.020 · doi:10.1016/j.jcmg.2017.04.020
- Chapelon-Abric, 2017, Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors, Arch Cardiovasc Dis, 110, 456, 10.1016/j.acvd.2016.12.014 · doi:10.1016/j.acvd.2016.12.014
- Takaya, 2014, Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement, Int J Cardiol, 176, 522, 10.1016/j.ijcard.2014.07.042 · doi:10.1016/j.ijcard.2014.07.042
- Fujita, 1990, A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities, Heart Vessels Suppl, 5, 16
- 10.2174/1573403X15666190725121246 · doi:10.2174/1573403x15666190725121246
- Joubert, 2017, Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis, JAMA Neurol, 74, 1336, 10.1001/jamaneurol.2017.2492 · doi:10.1001/jamaneurol.2017.2492
- 10.1186/s12883-016-0741-x · doi:10.1186/s12883-016-0741-x
- 10.1001/archinte.1997.00440370104011 · doi:10.1001/archinte.1997.00440370104011 · Paper page
- Metyas, 2014, Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab, Int J Rheum Dis, 17, 214, 10.1111/1756-185X.12122 · doi:10.1111/1756-185x.12122
- 10.1378/chest.124.5.2023 · doi:10.1378/chest.124.5.2023
- Thunold, 2017, Patient reported outcome measures (PROM) in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 34, 2
- Voortman, 2018, Determinaton of the smallest detectable change and minimal important change (MIC) for the small fiber neuropathy screening list (SFNSL) in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 35, 333
- Lower, 2019, Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome, Sarcoidosis Vasc Diffuse Lung Dis, 36, 254
Cited by
Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review
Belperio, J. A., Shaikh, F., Abtin, F. G., Fishbein, M. C., Weigt, S. S., Saggar, R., & Lynch, J. P. (2022) · JAMA · doi:10.1001/jama.2022.1570 · Cited by 191
Kidney manifestations of sarcoidosis.
Bonella, F., DM Vorselaars, A., & Wilde, B. (2024) · Journal of autoimmunity · doi:10.1016/j.jaut.2024.103207 · Cited by 32
Self-citation
Metadata
- Authors
- Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., Israel-Biet, D., Grutters, J. C., Drent, M., Culver, D. A., Bonella, F., Antoniou, K., Martone, F., Quadder, B., Spitzer, G., Nagavci, B., Tonia, T., Rigau, D., & Ouellette, D. R.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2021-06-17
- Volume
- 58
- Issue
- 6
- Pages
- 2004079
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W3166756865
- Cited by
- 629
- References
- 184
- FWCI
- 50.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ERS clinical practice guidelines on treatment of sarcoidosis. https://app.cochat.ai/papers/10.1183/13993003.04079-2020
- The paper
- Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., Israel-Biet, D., Grutters, J. C., Drent, M., Culver, D. A., Bonella, F., Antoniou, K., Martone, F., Quadder, B., Spitzer, G., . . . Ouellette, D. R. (2021). ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal. https://doi.org/10.1183/13993003.04079-2020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.